# PTHS (Pelthos Therapeutics Inc.) - SEC EDGAR Financial Statements

> Pelthos Therapeutics Inc. reported $51.29M in revenue and a net loss of $78.05M for the trailing twelve months ended September 30, 2026 (up 107.9% year over year), with a 83.2% gross margin and a -101.6% operating margin.

- Canonical: https://convexityos.com/fundamentals/PTHS
- Markdown: https://convexityos.com/fundamentals/PTHS.md
- SEC CIK: 0001919246
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:01 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001919246&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | TTM | $51.29M | +107.9% YoY |
| Operating Income | TTM | -$52.11M | -101.6% margin |
| Net Income | TTM | -$78.05M | -152.2% net margin |
| Diluted EPS | TTM | -$20.20 | Split-adjusted |
| Free Cash Flow | TTM | -$32.56M | -63.5% FCF margin |
| Cash & ST Investments | Sep 30, 2026 | $17.69M | Total debt: $3.10M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| **Revenue** | $16.80M | $0 | -- | -- |
| Cost of Revenue | $3.99M | $0 | -- | -- |
| **Gross Profit** | $12.81M | $0 | -- | -- |
| Research & Development | $1.23M | $1.18M | $2.58M | $392K |
| Selling, General & Admin | $42.45M | $6.39M | -- | -- |
| Total Operating Expenses | -- | $7.57M | $6.86M | $2.32M |
| **Operating Income** | -$32.43M | -$7.57M | -$6.86M | -$2.32M |
| **EBITDA** | -$30.14M | -$6.12M | -- | -- |
| Interest Expense | $3.01M | $786K | $309K | $136K |
| Income Before Tax | -$50.71M | -$7.96M | -$7.38M | -$2.46M |
| Income Tax Expense | -$7.39M | $0 | -- | -- |
| **Net Income** | -$43.32M | -$7.96M | -$7.38M | -$2.46M |
| Basic EPS | -$230.40 | -$142.70 | -$5,254.55 | $5,136.36 |
| **Diluted EPS** | -$230.40 | -$142.70 | -$5,254.55 | -- |
| Basic Shares Outstanding | 188.1K | 55.7K | 1.4K | 479 |
| Diluted Shares Outstanding | 188.1K | 55.7K | 1.4K | -- |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $15.39M | $15.60M | $10.91M | $9.39M | $7.41M | $0 | $0 | -- |
| Cost of Revenue | $1.66M | $3.61M | $1.67M | $1.67M | $2.32M | $0 | $0 | -- |
| **Gross Profit** | $13.73M | $11.99M | $9.23M | $7.72M | $5.09M | $0 | $0 | -- |
| Research & Development | $1.02M | $600K | $186K | $374K | $145K | $515K | $194K | $285K |
| Selling, General & Admin | $18.84M | $27.67M | $21.10M | $19.71M | $18.38M | $2.72M | $1.64M | -- |
| Total Operating Expenses | -- | -- | -- | -- | $22.77M | $3.23M | $1.83M | $1.82M |
| **Operating Income** | -$9.69M | -$17.32M | -$13.09M | -$12.00M | -$15.36M | -$3.23M | -$1.83M | -$1.82M |
| **EBITDA** | -$8.36M | -$16.00M | -$11.59M | -$10.79M | -$14.29M | -$2.89M | -$1.43M | -- |
| Interest Expense | $2.27M | $2.39M | $2.35M | $1.31M | $1.35M | $218K | $1.8K | $0 |
| Income Before Tax | -$7.89M | -$23.42M | -$10.24M | -$28.59M | -$16.70M | -$3.45M | -$1.97M | -$1.93M |
| Income Tax Expense | $0 | $0 | $0 | -$6.92M | -$465K | $0 | $0 | -- |
| **Net Income** | -$7.89M | -$23.42M | -$25.07M | -$21.66M | -$16.24M | -$3.45M | -$1.97M | -$1.93M |
| Basic EPS | -$2.04 | -$66.20 | -$30.90 | -- | -$5.30 | -$52.90 | -$32.10 | -- |
| **Diluted EPS** | -$2.04 | -$66.20 | -$30.90 | -- | -$5.30 | -$52.90 | -$32.10 | -- |
| Basic Shares Outstanding | 3.9M | 353.9K | 331.2K | -- | 3.1M | 65.2K | 61.3K | -- |
| Diluted Shares Outstanding | 3.9M | 353.9K | 331.2K | -- | 3.1M | 65.2K | 61.3K | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $17.97M | $513K | $100K | $100K |
| **Cash & Short-Term Investments** | $17.97M | $513K | $100K | $100K |
| Accounts Receivable, Net | $8.86M | $0 | -- | -- |
| Inventory | $23.57M | $0 | -- | -- |
| Other Current Assets | -- | $106K | -- | -- |
| **Total Current Assets** | $53.41M | $1.37M | $96K | $55K |
| Property, Plant & Equipment, Net | $9.59M | $0 | -- | -- |
| Goodwill | $24.68M | $0 | -- | -- |
| Intangible Assets | $39.47M | $0 | -- | -- |
| Other Non-Current Assets | $0 | -- | -- | -- |
| **Total Non-Current Assets** | $76.99M | $0 | $0 | $0 |
| **Total Assets** | $130.4M | $1.37M | $96K | $55K |
| Accounts Payable | $2.99M | $1.90M | -- | -- |
| Deferred Revenue (Current) | $966K | $0 | -- | -- |
| Other Current Liabilities | $3.84M | $0 | -- | -- |
| **Total Current Liabilities** | $25.99M | $4.08M | $6.54M | $3.76M |
| Deferred Revenue (Non-Current) | $1.28M | $0 | -- | -- |
| Other Non-Current Liabilities | $30.05M | $0 | -- | -- |
| **Total Non-Current Liabilities** | $65.52M | $0 | $0 | $0 |
| **Total Liabilities** | $91.52M | $4.08M | $6.54M | $3.76M |
| **Total Debt (incl. Leases)** | $3.39M | -- | -- | -- |
| Common Stock | $0 | $0 | $391 | $111 |
| Retained Earnings | -$64.79M | -$21.48M | -$13.52M | -$6.14M |
| Accumulated Other Comp. Income | $0 | -- | -- | -- |
| **Total Stockholders' Equity** | $38.88M | -$2.71M | -$6.45M | -$3.71M |
| Total Equity | $38.88M | -$2.71M | -$6.45M | -$3.71M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $17.69M | $24.19M | $31.98M | $17.97M | $14.20M | $59K | $131K | $513K |
| **Cash & Short-Term Investments** | $17.69M | $24.19M | $31.98M | $17.97M | $14.20M | $59K | $131K | $513K |
| Accounts Receivable, Net | $13.41M | $14.48M | $11.70M | $8.86M | -- | -- | -- | $0 |
| Inventory | $21.47M | $21.47M | $23.42M | $23.57M | $24.10M | -- | -- | $0 |
| Other Current Assets | -- | -- | -- | -- | $574K | -- | -- | $106K |
| **Total Current Assets** | $56.07M | $63.36M | $69.80M | $53.41M | $49.76M | $823K | $911K | $1.37M |
| Property, Plant & Equipment, Net | $8.51M | $8.88M | $9.31M | $9.59M | $10.17M | -- | -- | $0 |
| Goodwill | $24.68M | $24.68M | $24.68M | $24.68M | $30.62M | -- | -- | $0 |
| Intangible Assets | $36.34M | $37.40M | $38.44M | $39.47M | $32.52M | -- | -- | $0 |
| Other Non-Current Assets | $281K | -- | -- | $0 | -- | -- | -- | -- |
| **Total Non-Current Assets** | $72.75M | $74.00M | $75.58M | $76.99M | $76.67M | $0 | $0 | $0 |
| **Total Assets** | $128.8M | $137.4M | $145.4M | $130.4M | $126.4M | $823K | $911K | $1.37M |
| Accounts Payable | $3.72M | $5.85M | $6.15M | $2.99M | $5.67M | -- | -- | $1.90M |
| Deferred Revenue (Current) | $729K | $729K | $978K | $966K | $1.02M | -- | -- | $0 |
| Other Current Liabilities | -- | -- | $3.40M | $3.84M | $5.56M | -- | -- | $0 |
| **Total Current Liabilities** | $31.43M | $31.96M | $25.00M | $25.99M | $24.77M | $7.32M | $5.11M | $4.08M |
| Deferred Revenue (Non-Current) | $911K | $1.09M | $1.03M | $1.28M | -- | -- | -- | $0 |
| Other Non-Current Liabilities | -- | -- | $31.95M | $30.05M | $26.18M | -- | -- | $0 |
| **Total Non-Current Liabilities** | $103.6M | $106.9M | $85.27M | $65.52M | $43.41M | $0 | $0 | $0 |
| **Total Liabilities** | $135.0M | $138.9M | $110.3M | $91.52M | $68.18M | $7.32M | $5.11M | $4.08M |
| **Total Debt (incl. Leases)** | $3.10M | $3.19M | $3.29M | $3.39M | $2.85M | -- | -- | -- |
| Common Stock | $0 | $0 | $0 | $0 | -- | $67 | $621 | $0 |
| Retained Earnings | -$121.2M | -$113.3M | -$75.03M | -$64.79M | -$43.13M | -$26.89M | -$23.44M | -$21.48M |
| Accumulated Other Comp. Income | $3.32M | $2.08M | $3.19M | $0 | -- | -- | -- | -- |
| **Total Stockholders' Equity** | -$6.19M | -$1.50M | $19.27M | $38.88M | $58.25M | -$6.50M | -$4.20M | -$2.71M |
| Total Equity | -$6.19M | -$1.50M | $19.27M | $38.88M | $58.25M | -$6.50M | -$4.20M | -$2.71M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Net Income | -$43.32M | -$7.96M | -$7.38M | -$2.46M |
| Depreciation & Amortization | $2.29M | $1.46M | -- | -- |
| Stock-Based Compensation | $5.46M | $1.80M | $1.73M | $110K |
| Change in Receivables | -$8.81M | $0 | -- | -- |
| Change in Inventory | $1.78M | $0 | -- | -- |
| Change in Payables | $1.36M | $1.18M | -- | -- |
| **Operating Cash Flow** | -$22.59M | -$5.79M | -$981K | -$1.57M |
| Capital Expenditure | -$99K | $0 | -- | -- |
| **Free Cash Flow** | -$22.69M | -$5.79M | -- | -- |
| **Investing Cash Flow** | -$5.24M | $0 | -- | -- |
| Common Stock Issued | $0 | $5.97M | $255K | -- |
| Share Repurchases | $0 | -$75K | -- | -- |
| **Financing Cash Flow** | $45.34M | $6.21M | $1.02M | $1.62M |
| **Net Change in Cash** | $17.51M | $417K | $41K | $55K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$7.89M | -$23.42M | -$25.07M | -$21.66M | -$16.24M | -$3.45M | -$1.97M | -$1.93M |
| Depreciation & Amortization | $1.34M | $1.32M | $1.50M | $1.22M | $1.07M | $342K | $404K | -- |
| Stock-Based Compensation | $1.94M | $2.76M | $1.91M | $1.80M | $2.76M | $413K | $486K | $530K |
| Change in Receivables | $1.07M | -$2.78M | -$2.84M | -$870K | -$7.94M | $0 | $0 | -- |
| Change in Inventory | $203K | $1.22M | $156K | $393K | $1.39M | $0 | $0 | -- |
| Change in Payables | -$2.19M | -$338K | $3.16M | -$2.67M | $928K | $2.40M | $707K | -- |
| **Operating Cash Flow** | -$5.16M | -$7.66M | -$13.13M | -$6.25M | -$15.26M | -$447K | -$632K | -$670K |
| Capital Expenditure | -$60K | -$2.0K | -$194K | -$99K | $0 | $0 | $0 | -- |
| **Free Cash Flow** | -$5.22M | -$7.67M | -$13.32M | -$6.35M | -$15.26M | -$447K | -$632K | -- |
| **Investing Cash Flow** | -$60K | -$2.0K | -$194K | -$8.00M | $2.76M | $0 | $0 | -- |
| Common Stock Issued | -- | -- | -- | -- | -- | -- | -- | $0 |
| Share Repurchases | -- | -- | -- | -- | -- | -- | -- | $74K |
| **Financing Cash Flow** | -$1.17M | $0 | $27.52M | $18.02M | $26.69M | $375K | $250K | -$72K |
| **Net Change in Cash** | -$6.40M | -$7.67M | $14.20M | $3.77M | $14.19M | -$72K | -$382K | -$742K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| **Gross Margin** | 76.3% | -- | -- | -- |
| **Operating Margin** | -193.1% | -- | -- | -- |
| **Net Profit Margin** | -257.9% | -- | -- | -- |
| Return on Equity (ROE) | -111.4% | -- | -- | -- |
| Return on Assets (ROA) | -33.2% | -581.1% | -7657.1% | -4464.2% |
| Current Ratio | 2.05x | 0.34x | 0.01x | 0.01x |
| Quick Ratio | 1.15x | 0.34x | 0.02x | 0.03x |
| Debt to Equity | 0.09x | -- | -- | -- |
| EPS Growth (YoY) | -- | -- | -202.3% | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Gross Margin** | 83.2% | 78.6% | 79.6% | 76.3% | -- | -- | -- | -- |
| **Operating Margin** | -101.6% | -133.4% | -157.7% | -193.1% | -- | -- | -- | -- |
| **Net Profit Margin** | -152.2% | -199.5% | -239.8% | -257.9% | -- | -- | -- | -- |
| Return on Equity (ROE) | -- | -- | -344.8% | -111.4% | -40.5% | -- | -- | -- |
| Return on Assets (ROA) | -60.6% | -62.9% | -45.7% | -33.2% | -18.7% | -1098.4% | -807.9% | -581.1% |
| Current Ratio | 1.78x | 1.98x | 2.79x | 2.05x | 2.01x | 0.11x | 0.18x | 0.34x |
| Quick Ratio | 1.10x | 1.31x | 1.86x | 1.15x | 1.04x | 0.01x | 0.03x | 0.34x |
| Debt to Equity | -- | -- | 0.17x | 0.09x | 0.05x | -- | -- | -- |
| **Revenue Growth (YoY)** | +107.9% | -- | -- | -- | -- | -- | -- | -- |
| Gross Profit Growth (YoY) | +169.8% | -- | -- | -- | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
